Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
Pediatric Nephrology
Published in: Pediatric Nephrology 8/2019

01-08-2019 | Tremor | Clinical Quiz

Proteinuria in a patient with Graves’ disease: Questions

Authors: Aydilek Dagdeviren Cakir, Nur Canpolat, Seha Saygili, Isin Kilicaslan, Hande Turan, Oya Ercan, Olcay Evliyaoglu

Published in: Pediatric Nephrology | Issue 8/2019

Login to get access

Excerpt

A 15-year-old female presented with complaints of palpitation and tremor. On initial physical examination, her height, weight, and body mass index (BMI) were 159 cm (− 0.47 SD), 91 kg (3.95 SD), and 35.9 kg/m2 (3.47 SD), respectively. She had a diffuse goiter (grade 2) without proptosis, lid lag or lid retraction. There was a fine hand tremor. Her heart rate was 100 beats per minute and blood pressure was 130/90 mmHg (> 95th percentile). Other physical examination was unremarkable. Laboratory results showed an elevated free T4 (4.61 [0.82–1.75] ng/dL) and free T3 (17.2 [2.27–4.48] pg/mL) and a suppressed thyroid-stimulating hormone (TSH) (0.006 [0.5–4.33] μIU/mL). Immunological evaluation demonstrated the presence of thyroid antibodies against TSH receptor (TRAB) (17.7 [N 0–1.1] IU/mL), thyroid peroxidase (85 [N < 34] IU/mL), and thyroglobulin (340 [N < 115] IU/mL). Thyroid ultrasonography was compatible with thyroiditis. Hyperthyroidism associated with TRAB positivity suggested Graves’ disease and anti-thyroid treatment with methimazole was started. …
Literature
1.
Churg J, Habib R, White RH (1970) Pathology of the nephrotic syndrome in children: a report for the international study of kidney disease in children. Lancet 760:1299–1302CrossRefPubMed
2.
International Study of Kidney Disease in Children (1978) Nephrotic syndrome in children: prediction of histopathology from clinical and laboratory characteristics at time of diagnosis. A report of the International Study of Kidney Disease in Children. Kidney Int 13:159–165CrossRef
3.
Cameron JS (1990) Membranous nephropathy in childhood and its treatment. Pediatr Nephrol 4:193–198CrossRefPubMed
4.
Beck LH Jr, Bonegio RG, Lambeau G, Beck DM, Powell DW, Cummins TD, Klein JB, Salant DJ (2009) M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 361:11–21CrossRefPubMedPubMedCentral
5.
Beck LH Jr, Salant DJ (2010) Membranous nephropathy: recent travel and new roads ahead. Kidney Int 77:765–770CrossRefPubMed
6.
Cossey LN, Walker PD, Chris PL (2013) Phospholipase A2 receptor staining in pediatric idiopathic membranous glomerulopathy. Pediatr Nephrol 28:2307–2311CrossRefPubMed
7.
Kumar V, Ramachandran R, Kumar A, Nada R, Suri D, Gupta A, Kohli HS, Gupta KL, Jha V (2015) Antibodies to M-type phospholipase A2 receptor in children with idiopathic membranous nephropathy. Nephrology 20:572–575CrossRefPubMed
8.
O’Regan, Fong JSC, Kaplan BS, De Chadarevian JP, Lapointe N, Drummond KN (1976) Thyroid antigen -antibody nephritis. Clin Immunol Immunopathol 6:341–346CrossRefPubMed
9.
Jordan SC, Buckingham B, Sakai R, Olson D (1981) Studies of immune-complex glomerulonephritis mediated by human thyroglobulin. N Engl J Med 304:1212–1215CrossRefPubMed
10.
Horvath F Jr, Teague P, Gaffney EF, Mars DR, Fuller TJ (1979) Thyroid antigen associated immune complex glomerulonephritis in Graves’ disease. Am J Med 67:901–904CrossRefPubMed
11.
Ploth DW, Fitz A, Schnetzler D, Seidenfeld J, Wilson CB (1978) Thyroglobulin-anti- thyroglobulin immune complex glomerulonephritis complicating radioiodine therapy. Clin Immunol Immunopathol 9:327–334CrossRefPubMed
12.
Sato Y, Sasaki M, Kan R, Osaku A, Koyama S, Shibayama S, Sato M, Narumiya K, Takagi T, Kojima M (1989) Thyroid antigen-mediated glomerulonephritis in Graves’ disease. Clin Nephrol 31:49–52
13.
Shima Y, Nakanishi K, Togawa H, Obana M, Sako M, Miyawaki M, Nozu K, Iijima K, Yoshikawa N (2009) Membranous nephropathy associated with thyroid peroxidase antigen. Pediatr Nephrol 24:605–608
14.
Sasaki K, Yasuda K, Nakanishi K, Rakugi H, Isaka Y, Yamato M (2014) Membranous nephropathy secondary to Graves’ disease with deposits of thyroid peroxidase in an adult. CEN Case Rep 3:90–93CrossRefPubMed
15.
Keenswijk W, Degraeuwe E, Hoorens A, Dorpe JV, Vande Walle J (2018) A case of Graves’ disease associated with membranoproliferative glomerulonephritis and leukocytoclastic vasculitis. J Pediatr Endocrinol Metab 31(10):1165–1168CrossRefPubMed
16.
Shimamura Y, Tsushima T, Moniwa N, Hasegawa K, Ogawa Y, Takizawa H (2014) Tubulointerstitial nephritis and uveitis syndrome complicated by IgA nephropathy and Graves’ disease: a case report. J Med Case Rep 8:305CrossRefPubMedPubMedCentral
17.
Hasnain W, Stillman IE, Bayliss GP (2011) Minimal- change renal disease and Graves’ disease: a case report and literature review. NDT Plus 4:96–98PubMedPubMedCentral
18.
Vogt BA, Kim Y, Jennette JC, Falk RJ, Burke BA, Sinaiko A (1994) Antineutrophil cystoplasmic autoantibody–positive crescentic glomerulonephritis as a complication of treatment with propylthiouracil in children. J Pediatr 124:986–988CrossRefPubMed
19.
D’Cruz D, Chesser AM, Lightowler C, Comer M, Hurst MJ, Baker LR, Raine AE (1995) Antineutrophil cytoplasmic antibody-positive crescentic glomerulonephritis associated with anti-thyroid drug treatment. Br J Rheumatol 34:1090–1091CrossRefPubMed
20.
Hori Y, Arizono K, Hara S, Kawai R, Hara M, Yamada A (1996) Antineutrophil cytoplasmic autoantibody-positive crescentic glomerulonephritis associated with thiamazole therapy. Nephron 74:734–735CrossRefPubMed
21.
Lionaki S, Vlachopanos G, Georgalis A, Ziakas P, Gakiopoulou H, Petra C, Boletis J (2013) Lupus nephritis and non-Hodgkin lymphoma simultaneously diagnosed in a patient on methimazole. Lupus 22:95–98CrossRefPubMed
22.
Wang LC, Tsai WY, Yang YH, Chiang BL (2003) Methimazole-induced lupus erythematosus: a case report. J Microbiol Immunol Infect 36:278–281PubMed
23.
Reynolds LR, Bhathena D (1979) Nephrotic syndrome associated with methimazole therapy. Arch Intern Med 139:236–237CrossRefPubMed
24.
Ayalon R, Beck LH (2015) Membranous nephropathy: not just a disease for adults. Pediatr Nephrol 30:31–39CrossRefPubMed
25.
Kidney Disease Improving global outcomes (KDIGO) glomerulonephritis work group (2012) KDIGO clinical practice guideline for glomerulonephritis. Kidney Int Suppl 2:139–274CrossRef
26.
McQuarrie EP, Stirling CM, Geddes CC (2012) Idiopathic membranous nephropathy and nephrotic syndrome: outcome in the era of evidence –based therapy. Nephrol Dial Transplant 27:235–242CrossRefPubMed
27.
Remuzzi G, Chiurchiu C, Abbate M, Brusegan V, Bontempelli M, Ruggenenti P (2002) Rituximab for idiopathic membranous nephropathy. Lancet 360:923–924CrossRefPubMed
28.
Ruggenenti P, Chiurchiu C, Brusegan V, Abbate M, Perna A, Filippi C, Remuzzi G (2003) Rituximab in idiopathic membranous nephropathy: a one year prospective study. J Am Soc Nephrol 14:1851–1857
29.
Fervenza FC, Abraham RS, Erickson SB, Irazabal MV, Eirin A, Specks U, Nachman PH, Bergstralh EJ, Leung N, Cosio FG, Hogan MC, Dillon JJ, Hickson LJ, Li X, Cattran DC (2010) Rituximab therapy in idiopathic membranous nephropathy: a 2-year study. Clin J Am Soc Nephrol 5:2188–2198
30.
Ruggenenti P, Cravedi P, Chianca A, Perna A, Ruggiero B, Gaspari F, Rambaldi A,  Marasà M,  Remuzzi G (2012) Rituximab in idiopathic membranous nephropathy. J Am Soc Nephrol 23:1416–1425
31.
Pescovitz MD (2006) Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 6:859–866CrossRefPubMed
32.
Weigle WO, Nakamura RK (1969) Perpetuation of autoimmune thyroiditis and production of secondary renal lesions following periodic injections of aqueous preparations of altered thyroglobulin. Clin Exp Immunol 4:645–657PubMedPubMedCentral
33.
Polanco N, Gutierrez E, Covarsi A, Ariza F, Carreno A, Vigil A,  Baltar J, Fresnedo GF, Martín C, Pons S,  Lorenzo D,  Bernis C, Arrizabalaga P, Juárez GF, Barrio V,  Sierra M, Castellanos I, Espinosa M, Rivera F, Oliet A,Vega FF, Praga M(2010) Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. J Am Soc Nephrol 21:697–704
34.
De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC (2017) A proposal for a serology-based approach to membranous nephropathy. J Am Soc Nephrol 28:421–430CrossRefPubMed
35.
Fervenza FC, Sethi S, Specks U (2008) Idiopathic membranous nephropathy: diagnosis and treatment. Clin J Am Soc Nephrol 3:905–919CrossRefPubMed
36.
Troyanov S, Wall CA, Miller JA, Scholey JW, Cattran DC, Toronto Glomerulonephritis Registry Group (2004) Idiopathic membranous nephropathy: definition and relevance of a partial remission. Kidney Int 66:1199–1205CrossRefPubMed
37.
Bomback AS, Fervenza FC (2018) Membranous nephropathy: approaches to treatment. Am J Nephrol 47:30–42CrossRefPubMed
38.
Malatesta- Muncher R, Eldin KW, Beck LH Jr, Michael M (2018) Idiopathic membranous nephropathy in children treated with rituximab: report of two cases. Pediatr Nephrol 33:1089–1092CrossRefPubMed
Metadata
Title
Proteinuria in a patient with Graves’ disease: Questions
Authors
Aydilek Dagdeviren Cakir
Nur Canpolat
Seha Saygili
Isin Kilicaslan
Hande Turan
Oya Ercan
Olcay Evliyaoglu
Publication date
01-08-2019
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 8/2019
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-019-04220-y

Other articles of this Issue 8/2019

Pediatric Nephrology 8/2019 Go to the issue

Original Article

Risk factors for early onset peritonitis: the SCOPE collaborative

Original Article

Methylprednisolone or cyclosporine a in the treatment of Henoch-Schönlein nephritis: a nationwide study

Clinical Quiz

Nephrotic syndrome and mitochondrial disorders: Questions

Consensus Conference

Hemolytic uremic syndrome in a developing country: Consensus guidelines

Clinical Quiz

An adolescent patient presenting with hyponatremic seizure: Questions

Original Article

Association between the clinical presentation of congenital anomalies of the kidney and urinary tract (CAKUT) and gene mutations: an analysis of 66 patients at a single institution